{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:25:37Z","timestamp":1790220337720,"version":"4.1.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia & Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.blre.2023.101099","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:55:04Z","timestamp":1683593704000},"page":"101099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Thinking \u201coutside the germinal center\u201d: Re-educating T cells to combat follicular lymphoma"],"prefix":"10.1016","volume":"61","author":[{"given":"Swetha Kambhampati","family":"Thiruvengadam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Shouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.blre.2023.101099_bb0005","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"Suppl. 5","key":"10.1016\/j.blre.2023.101099_bb0010","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.blre.2023.101099_bb0015","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK\u2019s Haematological malignancy research network","volume":"112","author":"Smith","year":"2015","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.blre.2023.101099_bb0020","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(22)00033-3","article-title":"Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study","volume":"9","author":"Casulo","year":"2022","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101099_bb0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-020-0299-0","article-title":"Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience","volume":"10","author":"Mozas","year":"2020","journal-title":"Blood Cancer J"},{"issue":"23","key":"10.1016\/j.blre.2023.101099_bb0030","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2023.101099_bb0035","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1002\/1097-0142(19800515)45:10<2627::AID-CNCR2820451023>3.0.CO;2-0","article-title":"Spontaneous regression in non-Hodgkin\u2019s lymphoma","volume":"45","author":"Gattiker","year":"1980","journal-title":"Cancer."},{"issue":"23","key":"10.1016\/j.blre.2023.101099_bb0040","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.blre.2023.101099_bb0045","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood.V128.22.1777.1777","article-title":"Intervention versus observation: what is the appropriate endpoint? Assessment of endpoints in patients with advanced stage follicular lymphoma who are initially observed","volume":"128","author":"Soumerai","year":"2016","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101099_bb0050","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.blre.2023.101099_bb0055","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic specialized program of research excellence molecular epidemiology resource","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2023.101099_bb0060","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1084\/jem.20061292","article-title":"Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis","volume":"203","author":"Roulland","year":"2006","journal-title":"J Exp Med"},{"issue":"7360","key":"10.1016\/j.blre.2023.101099_bb0065","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature."},{"issue":"7337","key":"10.1016\/j.blre.2023.101099_bb0070","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature."},{"issue":"2","key":"10.1016\/j.blre.2023.101099_bb0075","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.blre.2023.101099_bb0080","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.blre.2023.101099_bb0085","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/ng.3473","article-title":"Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma","volume":"48","author":"Okosun","year":"2016","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.blre.2023.101099_bb0090","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","article-title":"Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma","volume":"121","author":"Green","year":"2013","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101099_bb0095","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"issue":"12","key":"10.1016\/j.blre.2023.101099_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"issue":"5","key":"10.1016\/j.blre.2023.101099_bb0105","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/s41375-018-0043-y","article-title":"Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma","volume":"32","author":"Araf","year":"2018","journal-title":"Leukemia."},{"issue":"7","key":"10.1016\/j.blre.2023.101099_bb0110","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia."},{"issue":"4","key":"10.1016\/j.blre.2023.101099_bb0115","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.3324\/haematol.2017.175059","article-title":"Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort","volume":"103","author":"Rimsza","year":"2018","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2023.101099_bb0120","series-title":"World Health Organization classification of Tumours","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"10","key":"10.1016\/j.blre.2023.101099_bb0125","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","article-title":"Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3","volume":"99","author":"Ott","year":"2002","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2023.101099_bb0130","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood.V101.3.1149","article-title":"Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive","volume":"101","author":"Bosga-Bouwer","year":"2003","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2023.101099_bb0135","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN guidelines(R) insights: B-cell lymphomas, version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"issue":"5","key":"10.1016\/j.blre.2023.101099_bb0140","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood."},{"issue":"27","key":"10.1016\/j.blre.2023.101099_bb0145","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2023.101099_bb0150","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.blre.2023.101099_bb0155","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101099_bb0160","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.16159","article-title":"M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy","volume":"188","author":"Lockmer","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2023.101099_bb0165","series-title":"Long-term outcomes of patients with follicular lymphoma is not fundamentally affected by KMT2D, EZH2, and Crebbp mutational status","author":"Bantilan","year":"2022"},{"issue":"7","key":"10.1016\/j.blre.2023.101099_bb0170","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41408-021-00521-4","article-title":"Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma","volume":"11","author":"Mondello","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.blre.2023.101099_bb0175","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood."},{"issue":"30","key":"10.1016\/j.blre.2023.101099_bb0180","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.blre.2023.101099_bb0185","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/blood-2017-11-816298","article-title":"Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA\/FIL study","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2023.101099_bb0190","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2023.101099_bb0195","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","article-title":"Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG","volume":"133","author":"Brady","year":"2019","journal-title":"Blood."},{"issue":"25","key":"10.1016\/j.blre.2023.101099_bb0200","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of Lenalidomide in B-cell non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2023.101099_bb0205","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2023.101099_bb0210","series-title":"Long-term efficacy and safety from the Copanlisib CHRONOS-1 study in patients with relapsed or refractory indolent B-cell lymphoma","author":"Dreyling","year":"2018"},{"issue":"4","key":"10.1016\/j.blre.2023.101099_bb0215","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.blre.2023.101099_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Transl Immunology"},{"issue":"1","key":"10.1016\/j.blre.2023.101099_bb0225","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101099_bb0230","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101099_bb0235","doi-asserted-by":"crossref","first-page":"10380","DOI":"10.1182\/blood-2022-156120","article-title":"3-year follow-up analysis of ZUMA-5: a phase 2 study of Axicabtagene Ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL)","volume":"140","author":"Neelapu","year":"2022","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101099_bb0240","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1182\/blood-2022-158024","article-title":"Long-term clinical outcomes and correlative efficacy analyses in patients (pts) with relapsed\/refractory follicular lymphoma (r\/r FL) treated with Tisagenlecleucel in the Elara trial","volume":"140","author":"Dreyling","year":"2022","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2023.101099_bb0245","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2021014375","article-title":"Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma","volume":"140","author":"Ghione","year":"2022","journal-title":"Blood."},{"issue":"22","key":"10.1016\/j.blre.2023.101099_bb0250","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2022008150","article-title":"Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma","volume":"6","author":"Salles","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2023.101099_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.09.022","article-title":"Assessment of healthcare resource utilization and hospitalization costs in patients with relapsed or refractory follicular lymphoma undergoing CAR-T cell therapy with Tisagenlecleucel: results from the ELARA study","volume":"29","author":"Fowler","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.blre.2023.101099_bb0260","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.blre.2023.101099_bb0265","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.clml.2021.07.002","article-title":"Real-world experience of Axicabtagene Ciloleucel and Tisagenlecleucel for relapsed or refractory aggressive B-cell lymphomas: a single-institution experience","volume":"21","author":"Ghafouri","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.blre.2023.101099_bb0270","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica."},{"issue":"10","key":"10.1016\/j.blre.2023.101099_bb0275","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101099_bb0280","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.blre.2023.101099_bb0285","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1007\/s12325-021-01838-z","article-title":"Access to chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma","volume":"38","author":"Snyder","year":"2021","journal-title":"Adv Ther"},{"issue":"19","key":"10.1016\/j.blre.2023.101099_bb0290","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood.2022016747","article-title":"Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma","volume":"140","author":"Thiruvengadam","year":"2022","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2023.101099_bb0295","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/bloodadvances.2022008097","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma","volume":"7","author":"Potnis","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101099_bb0300","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/EDBK_238693","article-title":"Chimeric antigen receptor T-cell therapies for aggressive B-cell lymphomas: current and future state of the art","volume":"39","author":"Abramson","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.blre.2023.101099_bb0305","series-title":"3-year follow-up analysis of ZUMA 5: A phase 2 study of axicabtagene ciloleucel (Axi-cel) in patients with relapsed\/refractory indolent non-hodgkin lymphoma","author":"SSea","year":"2022"},{"issue":"8","key":"10.1016\/j.blre.2023.101099_bb0310","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.blre.2023.101099_bb0315","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101099_bb0320","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2022-158404","article-title":"Odronextamab in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) grade 1-3a: results from a Prespecified analysis of the pivotal phase II study ELM-2","volume":"140","author":"Kim","year":"2022","journal-title":"Blood."},{"issue":"10306","key":"10.1016\/j.blre.2023.101099_bb0325","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet."},{"issue":"16","key":"10.1016\/j.blre.2023.101099_bb0330","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.blre.2023.101099_bb0335","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","article-title":"Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"61","author":"Coyle","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.blre.2023.101099_bb0340","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent Mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2023.101099_bb0345","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101099_bb0350","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41540-020-00145-7","article-title":"Mitigating the risk of cytokine release syndrome in a phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling","volume":"6","author":"Hosseini","year":"2020","journal-title":"NPJ Syst Biol Appl"},{"issue":"5","key":"10.1016\/j.blre.2023.101099_bb0355","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11050355","article-title":"Bispecific antibodies: a review of development, clinical efficacy and toxicity in B-cell lymphomas","volume":"11","author":"Salvaris","year":"2021","journal-title":"J Pers Med"},{"issue":"1","key":"10.1016\/j.blre.2023.101099_bb0360","article-title":"The role of bispecific antibodies in non-Hodgkin\u2019s lymphoma: from structure to prospective clinical use","volume":"11","author":"Tavarozzi","year":"2022","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.blre.2023.101099_bb0365","series-title":"Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed\/refractory follicular lymphoma who received atleast 2 prior therapies: Updated results frmo a pivotal phase II study","author":"Nea","year":"2022"},{"issue":"16_suppl","key":"10.1016\/j.blre.2023.101099_bb0370","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1200\/JCO.2022.40.16_suppl.7524","article-title":"Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R\/R) follicular lymphoma (FL): update from phase 1\/2 trial","volume":"40","author":"Falchi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101099_bb0375","series-title":"Subcutaneous Epcoritamab in combination with rituximab + Lenalidomide (R2) for first-line treatment of follicular lymphoma: Initial results from phase 1\/2 trial","author":"Falchi","year":"2022"},{"issue":"5","key":"10.1016\/j.blre.2023.101099_bb0380","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood."},{"issue":"19","key":"10.1016\/j.blre.2023.101099_bb0385","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1182\/blood.2020009686","article-title":"BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19\/CD3-bispecific antibody in CLL","volume":"138","author":"Mhibik","year":"2021","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101099_bb0390","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2021-145694","article-title":"Mosunetuzumab in combination with Lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed\/refractory follicular lymphoma: initial results from a phase Ib study","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood."},{"issue":"15_suppl","key":"10.1016\/j.blre.2023.101099_bb0395","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1200\/JCO.2021.39.15_suppl.7520","article-title":"Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib\/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed\/refractory (R\/R) B-cell non-Hodgkin\u2019s lymphoma (B-NHL)","volume":"39","author":"Budde","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2023.101099_bb0400","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2023.101099_bb0405","series-title":"Recent bendamustine treatment before aphersis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","author":"Le","year":"2022"},{"issue":"12","key":"10.1016\/j.blre.2023.101099_bb0410","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/cncr.31374","article-title":"Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure","volume":"124","author":"Smith","year":"2018","journal-title":"Cancer."},{"issue":"6","key":"10.1016\/j.blre.2023.101099_bb0415","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous transplantation in follicular lymphoma with early therapy failure: a national LymphoCare study and Center for International Blood and Marrow Transplant Research Analysis","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2023.101099_bb0420","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/10428194.2018.1473576","article-title":"Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world","volume":"60","author":"Manna","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.blre.2023.101099_bb0425","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German low grade lymphoma study group","volume":"24","author":"Jurinovic","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2023.101099_bb0430","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/hon.2553","article-title":"Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment","volume":"36","author":"Jimenez-Ubieto","year":"2018","journal-title":"Hematol Oncol"},{"issue":"7","key":"10.1016\/j.blre.2023.101099_bb0435","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2023.101099_bb0440","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2023.101099_bb0445","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR T cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101099_bb0450","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1182\/blood-2022-169872","article-title":"Impact of a validated composite comorbidity score on outcomes in patients treated with CAR T-cell therapy for diffuse large B cell lymphoma (DLBCL): a multicenter real-world evidence (RWE) study","volume":"140","author":"Shouse","year":"2022","journal-title":"Blood."},{"issue":"16_suppl","key":"10.1016\/j.blre.2023.101099_bb0455","doi-asserted-by":"crossref","first-page":"7526","DOI":"10.1200\/JCO.2022.40.16_suppl.7526","article-title":"Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed\/refractory B-cell non-Hodgkin lymphomas","volume":"40","author":"Schuster","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2023.101099_bb0460","article-title":"Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL","author":"Zurko","year":"2022","journal-title":"Blood Adv"},{"issue":"511","key":"10.1016\/j.blre.2023.101099_bb0465","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw9414","article-title":"CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies","volume":"11","author":"Qin","year":"2019","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.blre.2023.101099_bb0470","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1182\/bloodadvances.2022008560","article-title":"Generation of a humanized afucosylated BAFF-R antibody with broad activity against human B-cell malignancies","volume":"7","author":"Dong","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101099_bb0475","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022009309","article-title":"A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma","author":"Shouse","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.blre.2023.101099_bb0480","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/cncr.31264","article-title":"Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the lymphoma working party of the EBMT and the lymphoma committee of the CIBMTR","volume":"124","author":"Sureda","year":"2018","journal-title":"Cancer."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T15:33:16Z","timestamp":1724772796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":96,"alternative-id":["S0268960X23000607"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101099","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thinking \u201coutside the germinal center\u201d: Re-educating T cells to combat follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101099"}}